Type
Internal restructuring
Country
Malta
Region
Location of affected unit(s)
Ħal Far and Bulebel
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

205 jobs
Number of planned job losses
Job loss
Announcement Date
24 November 2016
Employment effect (start)
24 November 2016
Foreseen end date
31 December 2017

Description

Pharmaceutical manufacturer Actavis has announced that it will be cutting a total of 205 jobs from its two sites in Malta. It has been reported that the site in Ħal Far will be shut down following 170 job cuts, consisting primarily of operators, lab analysts and employees in the IT and human resources departments. The other Actavis site in Bulebel will be cutting a further 35 jobs.

Actavis, which was acquired by Teva Pharmaceuticals Industries in August 2016, stated that these redundancies are the result of a consolidation exercise to optimize network efficiency, reduce costs, and to better meet market demand.    

The Government and representing union, the GWU, claimed that they had not been consulted about Teva’s plans to cut jobs. The Government announced that it has already identified a number of alternative employment opportunities for those affected by these redundancies, while the GWU declared that it will continue to defend the interests of its workers and help them seek alternative employment.    


Sources

  • 24 November 2016: Times of Malta
  • 24 November 2016: TVM

Citation

Eurofound (2016), Actavis, Internal restructuring in Malta, factsheet number 89238, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/89238.